Boraschi D.,National Research Council Italy |
Aguado M.T.,Initiative for Vaccine Research |
Dutel C.,Fondation Merieux |
Goronzy J.,Stanford University |
And 4 more authors.
Science Translational Medicine | Year: 2013
Prolonged life expectancy in the 20th century has been one of humankind's greatest triumphs. However, the substantial increase in the human life span has ushered in a new concern: healthy aging. Because infectious diseases prominently contribute to morbidity in the particularly vulnerable elderly population, strategies for preventing these diseases would have a clear impact on improving healthy aging. Thus, vaccines and immunization strategies tailored for the elderly population are needed, and vaccines should be developed to take into consideration the peculiar age-induced variations of immune responsiveness. The conference "Ageing and Immunity" recently held in Siena, Italy, has reviewed and discussed several possible causes of immune senescence, as well as strategies for counteracting this waning of immune responsiveness and for restoring immunocompetence. In addition, examples of diseases that should be targeted by vaccination in the senior population were considered.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-07-2014 | Award Amount: 20.85M | Year: 2014
COMPARE aims to harness the rapid advances in molecular technology to improve identification and mitigation of emerging infectious diseases and foodborne outbreaks. To this purpose COMPARE will establish a One serves all analytical framework and data exchange platform that will allow real time analysis and interpretation of sequence-based pathogen data in combination with associated data (e.g. clinical, epidemiological data) in an integrated inter-sectorial, interdisciplinary, international, one health approach. The framework will link research, clinical and public health organisations active in human health, animal health, and food safety in Europe and beyond, to develop (i) integrated risk assessment and risk based collection of samples and data, (ii) harmonised workflows for generating comparable sequence and associated data, (iii) state-of-the-art analytical workflows and tools for generating actionable information for support of patient diagnosis, treatment, outbreak detection and -investigation and (iv) risk communication tools. The analytical workflows will be linked to a flexible, scalable and open-source data- and information platform supporting rapid sharing, interrogation and analysis of sequence-based pathogen data in combination with other associated data. The system will be linked to existing and future complementary systems, networks and databases such as those used by ECDC, NCBI and EFSA. The functionalities of the system will be tested and fine tuned through underpinning research studies on priority pathogens covering healthcare-associated infections, food-borne disease, and (zoonotic) (re-) emerging diseases with epidemic or pandemic potential. Throughout the project, extensive consultations with future users, studies into the barriers to open data sharing, dissemination and training activities and studies on the cost-effectiveness of the system will support future sustainable user uptake.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: INFRAIA-1-2014-2015 | Award Amount: 12.17M | Year: 2015
The overall objective will be to create and mobilise an International network of high calibre centres around a strong European group of institutes selected for their appropriate expertises, to collect, amplify, characterise, standardise, authenticate, distribute and track, mammalian and other exotic viruses. The network of EVAg laboratories including 25 institutions represents an extensive range of virological disciplines. The architecture of the consortium is based on the association of capacities accessible to the partners but also to any end-users through the EVAg web-based catalogue. This concept has been elaborated and tested for its efficiency during the successful EVA project (FP7). The project will integrate more facilities dedicated to high risk pathogen (HRP) manipulation (1 in EVA, 13 in EVAg) The access to products derived from those HRP will be enhanced and for instance the production of diagnostic reagents will be facilitated. The new project will also provide access to high containment biosafety facilities to carry out in vivo studies of infectious disease using natural or models hosts, to look at prophylactic or therapeutic control measures and to develop materials for the evaluation of diagnostic tests, meaning an extensive capacity to service and to training. EVAg will also link up with other network-based virus-associated programmes that exist globally. However, looking further ahead, EVAg is conceived ultimately to be an open entity aiming at developing synergies and complementarity capabilities in such a way as to offer an improved access to researchers. This project will generate the largest collection of mammalian viruses in the world and move beyond the current state-of-the-art to provide an increasingly valuable resource and service to the worlds scientific community, including government health departments, higher education institutes, industry and, through information systems, the general public.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-22-2016 | Award Amount: 12.56M | Year: 2016
The ZikaPLAN initiative combines the strengths of 25 partners in Latin America, North America, Africa, Asia, and various centres in Europe to address the urgent research gaps (WP 1-8) in Zika, identifying short-and long term solutions (WP 9-10) and building a sustainable Latin-American EID Preparedness and Response capacity (WP 11-12). We will conduct clinical studies to further refine the full spectrum and risk factors of congenital Zika syndrome (including neurodevelopmental milestones in the first 3 years of life), and delineate neurological complications associated with Zika due to direct neuroinvasion and immune-mediated responses. Laboratory based research to unravel neurotropism, investigate the role of sexual transmission, determinants of severe disease, and viral fitness will envelop the clinical studies. Burden of disease and modelling studies will assemble a wealth of data including a longitudinal cohort study of 17,000 subjects aged 2-59 in 14 different geographic locations in Brazil over 3 years. Data driven vector control and vaccine modelling as well as risk assessments on geographic spread of Zika will form the foundation for evidence-informed policies. The Platform for Diagnostics Innovation and Evaluation will develop novel ZIKV diagnostic tests in accordance with WHO Target Product Profiles. Our global network of laboratory and clinical sites with well-characterized specimens is set out to accelerate the evaluation of the performance of such tests. Based on qualitative research, we will develop supportive, actionable messages to affected communities, and develop novel personal protective measures. Our final objective is for the Zika outbreak response effort to grow into a sustainable Latin-American network for emerging infectious diseases research preparedness. To this end we will engage in capacity building in laboratory and clinical research, collaborate with existing networks to share knowledge and tackle regulatory and other bottlenecks.
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2009.9.1 | Award Amount: 2.96M | Year: 2011
There is widespread agreement that ICT services have the potential to play a major role in furthering social development in developing economies such as those in Africa. However, while there is a great deal of potential and opportunity, the amount and scope of actual mobile ICT services currently in existence in African countries is very limited.\n\nThe Mobile Web for Social Development Roadmap, recently published as a result of the FP7 Digital World Forum project, makes it clear that realizing the potential of mobile ICT services requires addressing two major types of challenges:\n1. The leveraging of content that is locally relevant; and\n2. The removal of a range of access barriers, notably limitations related to access channels, literacy, and languages.\n\nVOICES intends to take a major step forward in realizing the potential of mobile ICT services particularly in the African context and resolve key challenges outlined in the Mobile Web for Social Development Roadmap. To this end, the objectives of VOICES are to deliver:\n Open and wider access: VOICES will improve voice-based access to content and mobile ICT services by building a toolbox for the development of voice services.\n Integration of Local Community Radios and ICT.\n Better support of languages: It will deliver tool support and methodology for under researched and under resourced African languages.\n Long-term sustainability: To ensure the local adoption and exploitation of the VOICES tools and methods beyond the project, it will provide a sustainable architecture.\n Faster uptake: VOICES will furthermore enhance uptake by delivering a mobile training lab that offers capacity building for local partners.\n\nVOICES will demonstrate the fitness of its results for adaptation to the African context by extensive local pilots and associated community building, namely through the focus on health services in Senegal, and agricultural and regreening knowledge sharing in the Sahel countries.
Vernet G.,Fondation Merieux |
Altmann D.M.,Imperial College London |
Doumbo O.,Malaria Research and Training Center |
Bhutta Z.A.,Aga Khan University |
And 2 more authors.
Emerging Infectious Diseases | Year: 2014
Antimicrobial drug resistance is usually not monitored in under-resourced countries because they lack surveillance networks, laboratory capacity, and appropriate diagnostics. This accelerating problem accounts for substantial number of excess deaths, especially among infants. Infections particularly affected by antimicrobial drug resistance include tuberculosis, malaria, severe acute respiratory infections, and sepsis caused by gram-negative bacteria. Nonetheless, mapping antimicrobial drug resistance is feasible in under-resourced countries, and lessons can be learned from previous successful efforts. Specimen shipping conditions, data standardization, absence of contamination, and adequate diagnostics must be ensured. As a first step toward solving this problem, we propose that a road map be created at the international level to strengthen antimicrobial resistance surveillance in under-resourced countries. This effort should include a research agenda; a map of existing networks and recommendations to unite them; and a communication plan for national, regional, and international organizations and funding agencies.
Agency: European Commission | Branch: FP7 | Program: CSA-CA | Phase: HEALTH-2007-2.3.2-11 | Award Amount: 1.17M | Year: 2009
A number of new vaccines are being developed against Poverty-Related infectious diseases of major public health importance at a global level. The development of all those vaccines is facing the same kind of challenges and gaps, which still prevent 1) the establishment of readily accessible formulation and scale-up process development capacity for neglected diseases vaccines. 2) the establishment of a systematic approach for prioritizing formulation of vaccine candidates using accepted pre-clinical criteria. 3) the development of information-sharing tools to strengthen connections between the scientists, the developers and the clinical investigators. To address those challenges, the European vaccine community needs to establish a shared vision and goals and to identify the activities that could address some of the above-mentioned challenges. The cooperation between the different groups of PRD vaccine developers can bring innovative approaches for accelerating the development of effective vaccines. Among those challenges, several can be addressed through coordination across poverty related diseases, such as: 1) difficulties in accessing to some technology platforms, such as synthetic peptides, recombinant proteins, for GMP development, and therefore in making rationale decisions on the best industrial approach for the pharmaceutical development, 2) difficulties in accessing certain know-how, such as lyophilisation and lack of formulation platform accessible to academic group, 3) difficulties to access to some delivery platforms, such as adjuvants, virus-like particles for GMP development and/or to assess the quality and regulatory compliance of those platforms, 4) difficulties to harmonise the safety data collection, 5) the insufficient number of trained scientists able to play leadership in vaccine development
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: HCO-04-2014 | Award Amount: 2.90M | Year: 2015
GLOPID-R-Sec is the secretariat to the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R). The secretariat will be staffed by Fondation Mrieux and the University of Oxford, and will provide the following support activities to the GloPID-R member organisations, working groups and commitees: - Organizational, financial-administrative and secretarial support activities to the GloPID-R governance structure ensuring efficient information exchange amongst all GloPID-R members and stakeholders; - Connecting GloPID-R to relevant research networks, and mapping of their current scientific and operational status in terms of research preparedness in support of the development of operational readiness towards initiating a rapid coordinated international research response to emerging infectious disease outbreaks, This will include mapping of different, interrelated barriers (scientific, infrastructural, human resource capacities and skills, political, ethical, regulatory, legal, societal, ICT, financial); - Assisting GloPID-R in the development of a strategic agenda and a readiness plan that serve as common and central guiding documents for all members and external stakeholders. - Developing and implementing a comprehensive communication and dissemination plan for information sharing within the GloPID-R community, to ensure stakeholders are well-informed and aligned, and to raise public awareness about and engagement in the initiative. Fondation Mrieux and the University of Oxford can build on ongoing efforts and the results thereof of high relevance to GloPID-R, in their respective lined networks such as AVIESAN and ISARIC. Fondation Mrieux will be the coordinator of GloPID-R-Sec, with its office at Lyon, France as the central point of contact of the Secretariat.